Cryosurgery and 5-Fluorouracil Combination Therapy for Treatment of Bowen's Disease and Superficial Basal Cell Carcinoma

J Drugs Dermatol. 2023 Dec 1;22(12):1166-1171. doi: 10.36849/JDD.7378.

Abstract

Background: Non-melanoma skin cancer (NMSC), which includes both Bowen's disease (BD) and superficial basal cell carcinoma (sBCC), is the most commonly diagnosed cancer in Canada. BD and sBCC are amenable to minimally invasive treatments however, large-scale studies assessing long-term outcomes are lacking, particularly regarding the timing and duration of non-invasive combination treatments.

Objective: Examine the clinical cure rate of BD and sBCC using a combination treatment consisting of a single cycle of cryotherapy followed by a three to four-week course of topical 5-fluorouracil (5-FU).

Methods: Retrospective chart review at a single center. Inclusion criteria included histology-proven sBCC or BD treated with either a combination protocol, cryosurgery, or 5-FU alone.

Results: 310 biopsy-confirmed cases of BD and 176 biopsy-confirmed cases of sBCC were analyzed. Of these, 229 cases of BD and 61 cases of sBCC were treated with cryosurgery and immediate 5-FU application, yielding a clearance rate of 90% and 86.9% at 6 months from initial treatment.

Conclusion: Cryosurgery followed by immediate 5-FU use may be an effective mode of treatment for BD and sBCC, negating the need for invasive procedures and allowing for increased accessibility. Further studies with longer follow-up intervals, comparisons with other non-invasive treatments, and evidence of histologic cure are required. J Drugs Dermatol. 2023;22(12):1166-1171. doi:10.36849/JDD.7378.

MeSH terms

  • Bowen's Disease* / diagnosis
  • Bowen's Disease* / drug therapy
  • Carcinoma, Basal Cell* / drug therapy
  • Carcinoma, Basal Cell* / surgery
  • Cryosurgery*
  • Fluorouracil / therapeutic use
  • Humans
  • Retrospective Studies
  • Skin Neoplasms* / diagnosis
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / surgery
  • Treatment Outcome

Substances

  • Fluorouracil